ATE473283T1 - Dna-expressionsvektoren - Google Patents

Dna-expressionsvektoren

Info

Publication number
ATE473283T1
ATE473283T1 AT01980716T AT01980716T ATE473283T1 AT E473283 T1 ATE473283 T1 AT E473283T1 AT 01980716 T AT01980716 T AT 01980716T AT 01980716 T AT01980716 T AT 01980716T AT E473283 T1 ATE473283 T1 AT E473283T1
Authority
AT
Austria
Prior art keywords
expression vectors
dna expression
vectors
host cells
intron
Prior art date
Application number
AT01980716T
Other languages
English (en)
Inventor
Ian Catchpole
Jonathan Ellis
Peter Ertl
John Rhodes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE473283T1 publication Critical patent/ATE473283T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
AT01980716T 2000-11-06 2001-11-02 Dna-expressionsvektoren ATE473283T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0027088.4A GB0027088D0 (en) 2000-11-06 2000-11-06 DNA expression vectors
PCT/GB2001/004912 WO2002036792A2 (en) 2000-11-06 2001-11-02 Dna expression vectors

Publications (1)

Publication Number Publication Date
ATE473283T1 true ATE473283T1 (de) 2010-07-15

Family

ID=9902639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01980716T ATE473283T1 (de) 2000-11-06 2001-11-02 Dna-expressionsvektoren

Country Status (10)

Country Link
US (2) US20040082531A1 (de)
EP (1) EP1334201B1 (de)
JP (1) JP2004512837A (de)
AT (1) ATE473283T1 (de)
AU (1) AU2002212505A1 (de)
CA (1) CA2427952A1 (de)
DE (1) DE60142519D1 (de)
ES (1) ES2346850T3 (de)
GB (1) GB0027088D0 (de)
WO (1) WO2002036792A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498739A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
PL1685251T3 (pl) * 2003-10-10 2014-07-31 Powderject Vaccines Inc Konstrukty kwasu nukleinowego
GB0400965D0 (en) * 2004-01-16 2004-02-18 Glaxo Group Ltd Promoter
US7785875B2 (en) * 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
US20060045885A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M Method of eliciting an immune response against HIV
US7429480B2 (en) * 2005-01-10 2008-09-30 National Taiwan University Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques
JP2008527001A (ja) * 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
CA2621917A1 (en) * 2005-09-08 2007-03-15 The Research Foundation For Microbial Diseases Of Osaka University Promoter for introducing gene into lymphocyte or blood cell and application thereof
BRPI0715581A2 (pt) 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
CL2007003743A1 (es) 2006-12-22 2008-07-11 Bayer Cropscience Ag Composicion que comprende fenamidona y un compuesto insecticida; y metodo para controlar de forma curativa o preventiva hongos fitopatogenos de cultivos e insectos.
DK2137210T3 (en) 2007-03-02 2017-01-30 Glaxosmithkline Biologicals Sa Hitherto unknown method and compositions
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
KR20000006334A (ko) * 1998-06-26 2000-01-25 이선경 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터
DE60118798T2 (de) * 2000-10-13 2007-04-12 Chiron Corp., Emeryville Fragmente des introns a des cytomegalovirus

Also Published As

Publication number Publication date
US20040082531A1 (en) 2004-04-29
DE60142519D1 (de) 2010-08-19
JP2004512837A (ja) 2004-04-30
WO2002036792A2 (en) 2002-05-10
CA2427952A1 (en) 2002-05-10
WO2002036792A3 (en) 2002-09-06
AU2002212505A1 (en) 2002-05-15
GB0027088D0 (en) 2000-12-20
ES2346850T3 (es) 2010-10-21
US20090130126A1 (en) 2009-05-21
EP1334201A2 (de) 2003-08-13
EP1334201B1 (de) 2010-07-07

Similar Documents

Publication Publication Date Title
ATE473283T1 (de) Dna-expressionsvektoren
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
DE50312946D1 (de) Difluormethyl thiazolyl carboxanilide
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
DE69732309D1 (de) Primerzusammensetzungen für den Dentalbereich
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
WO2002044320A3 (en) Human elongase genes and uses thereof
EP1090294A4 (de) Verfahren um die anwesenheit von krebs in einer probe zu bestimmen durch nachweis der expression eines ssx-gens und peptiden, die von ssx oder ny-eso-1 abgeleitet sind
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
DK1147212T3 (da) T-hjælpecelle-epitoper
SG142300A1 (en) Promoters for expression in modified vaccinia virus ankara
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
TR200102655T2 (tr) Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen.
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
GB2349150B (en) Expression of DNA or proteins in C. Elegans
DE50303586D1 (de) Methylthiophencarboxanilide
NO20023914D0 (no) Preparater for anvendelse ved regulering av Parkin- genaktiviteten
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
DE60027419D1 (de) Regulatorische Sequenzen des humanen MCP-1 Gens
WO2002033058A3 (en) Novel cysteine proteases and uses thereof
DK1257658T3 (da) Metode til at öge genekspression i transfekterede gener

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties